BiotechTube
SymbioCellTech

SymbioCellTech

San Diego, United States· Est.
symbiocelltech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7M

Overview

SymbioCellTech is a private, preclinical-stage biotech based in San Diego, founded in 2018, focused on curing diabetes without immunosuppression. Its patented 'Neo-Islet' platform creates hybrid cell clusters that engraft and provide immune-isolated insulin secretion. The company has demonstrated promising preclinical proof-of-concept, including in diabetic dogs, and is targeting human clinical trials. It is a 2024 winner of the American Diabetes Association's Innovation Challenge Award.

DiabetesEndocrinology

Technology Platform

Patented 'Neo-Islet' platform combining allogeneic pancreatic beta cells with mesenchymal stem cells (MSCs) to create immune-privileged, insulin-secreting cell clusters for transplantation without immunosuppression.

Funding History

2
Total raised:$7M
Series A$5.2M
Seed$1.8M

Opportunities

The global diabetes market is vast, with a multi-billion dollar opportunity for a one-time, curative therapy that eliminates daily insulin injections and prevents complications.
Success would represent a paradigm shift from chronic disease management to a potential functional cure, commanding premium pricing and significantly reducing long-term healthcare costs.

Risk Factors

Key risks include clinical failure in human trials despite promising animal data, challenges in scaling up consistent GMP manufacturing of live cell clusters, regulatory hurdles for a novel biologic, and intense competition from other diabetes cure approaches.
As a pre-revenue company, it also faces significant financing risk.

Competitive Landscape

SCT competes with other cell therapy approaches (e.g., Vertex's VX-880 stem cell-derived islets, which require immunosuppression), islet encapsulation device companies (like ViaCyte), and immune-tolerance therapies. Its key differentiator is the 'natural encapsulation' via MSCs to avoid both immunosuppression and foreign-body reactions to devices.

More companies in Cell & Gene Therapy →More companies in United States →